The new review of the most notable patents disputes in Life Sciences in EAEU and CIS.

• pdf, 8.90 Mb

April 10^th, 2025 annual conference Pharmaceuticals – 2025: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2024 and what awaits us in 2025.

The State Duma is considering the bill No. 818556-8 “On Amendments to Part Four of the Civil Code of the Russian Federation” (the “Bill”), the authors of which propose to amend the procedure for making decisions on the use of inventions, utility models and industrial designs (“Objects of patent rights”) established by Article 1360 of the Civil Code of the Russian Federation.

The new review of the most notable patents disputes in Life Sciences in Russian and the CIS.

• pdf, 2.52 Mb

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.

On November 21- 22, 2024, Moscow will host the IX Conference “Legal Business of Russia 2024” with Lidings’ partner Boris Malakhov taking part as an invited expert.

On November 7, 2024, Lidings held a round table discussion " Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets" as part of the business program of the Forum "Under One Sun: Russia-India. Business and Culture ", which took place in Delhi, November 6 - 8, 2024.

Highlights of the event in our overview.

On 6-8 November 2024 the international forum “Under One Sun: Russia-India. Business and Cultur” will take place in Delhi, India withing the 100th anniversary of the Russian Association for International Cooperation. The event is organized on the initiative of the Ministry of Foreign Affairs of the Russian Federation and the Trade Mission in India with the support of Lidings as a co-organizer of the business discussion.

During the forum on November 7 Lidings will hold a special round table “Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets” moderated by Lidings’ partner Boris Malakhov and counsel Natalya Thotahewage.

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.

The new review of the most notable patents disputes in Life Sciences in Russian and the CIS.

• pdf, 2.52 Mb